Primary nonadherence to statin therapy: Patients' perceptions

American Journal of Managed Care

Volumn 19, Issue 4, 2013, Pages

  Harrison, Teresa N ^a   Derose, Stephen F ^a   Cheetham, T Craig ^b   Chiu, Vicki ^a   Vansomphone, Southida S ^b   Green, Kelley ^c   Tunceli, Kaan ^d   Scott, Ronald D ^f   Marrett, Elizabeth ^e   Reynolds, Kristi ^a  

^a Kaiser Permanente Southern California ^*  (United States)

^b Pharmacy Analytic Services   (United States)

^c KAISER PERMANENTE   (United States)

^d Global Health Outcomes Merck   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON PRESCRIPTION DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEAR; FEMALE; HEALTH LITERACY; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERCEPTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEMI STRUCTURED INTERVIEW; TELECONSULTATION; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUALITATIVE RESEARCH;

EID: 84877774940     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kochanek KD XJ, Murphy SL, Miniño AM, Kung HC. Deaths: Preliminary data for 2009. National vital statistics reports; vol 59 no 4. Hyattsville, MD: National Center for Health Statistics; 2011.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934): 1383-1389.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7-22.
6. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol. 2006;98(7):923-928. (Pubitemid 44402260)
7. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-1781.
8. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a lowcost statin era. Circulation. 2011;124(2):146-153.
9. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42(9):1208-1215.
10. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-254.
11. Fischer MA, Stedman MR, Lii J, et al. Primary medication nonadherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290.
12. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation.2008;117(8): 1028-1036.
13. Karter AJ, Parker MM, Moffet HH, et al. New prescription medicationgaps: a comprehensive measure of adherence to new prescriptions.Health Serv Res. 2009;44(5, pt 1):1640-1661.
14. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4):311-316. (Pubitemid 47387472)
15. McHorney CA, Spain CV. Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect. 2011;14(3):307-320.
16. Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary non-adherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27(1):57-64.
17. Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153(10): 633-640.
18. Cheetham TC, Niu F, Green K, et al. Primary non-adherence to statin medications in a managed care organization. J Manage Care Pharm. 2013 (In press).
19. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421.
20. Fung V, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4-10.
21. Tolmie EP, Lindsay GM, Kerr SM, et al. Patients' perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative study. Eur J Cardiovasc Nurs. 2003;2(2):141-149. (Pubitemid 36809167)
22. Derose SF, Green K, Marrett E, et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med. 201;173(1):38-43.
23. Gadkari AS, McHorney CA. Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin. 2010; 26(3):683-705.
24. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-314.
25. Chew LD, Griffin JM, Partin MR, et al. Validation of screening questions for limited health literacy in a large VA outpatient population. J Gen Intern Med. 2008;23(5):561-566.
26. Sarkar U, Karter AJ, Liu JY, et al. The literacy divide: health literacy and the use of an internet-based patient portal in an integrated health system-results from the diabetes study of northern California (DISTANCE). J Health Commun. 2010;15(suppl 2):183-196.
27. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011(1):CD004816.
28. Ekedahl A, Mansson N. Unclaimed prescriptions after automated prescription transmittals to pharmacies. Pharm World Sci. 2004;26(1):26-31. (Pubitemid 38250177)
29. Hamilton WR, Hopkins UK. Survey on unclaimed prescriptions in a community pharmacy. J Am Pharm Assoc (Wash). 1997;NS37(3):341-345.
30. Kinnaird D, Cox T, Wilson JP. Unclaimed prescriptions in a clinic with computerized prescriber order entry. Am J Health Syst Pharm. 2003;60(14):1468-1470. (Pubitemid 44712936)
31. Papke J. Unclaimed prescriptions requisitioned through provider order entry. J Managed Care Pharm. 1999;498-502.